Navigation Links
FDA Moves to Speed Development of Artificial Pancreas Systems

By Steven Reinberg
HealthDay Reporter

THURSDAY, Dec. 1 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday issued new guidelines aimed at helping speed up the development of artificial pancreas systems.

If they become a reality, such technologies could make a huge difference for people with type 1 diabetes, who need insulin injections to control their blood sugar and survive.

Artificial pancreas systems combine current technologies for continuous blood sugar monitoring and pumps to deliver insulin as needed. These systems are designed to keep patients' insulin levels within normal ranges, by reacting to changes in blood sugar.

So far, however, equipment problems, computer glitches and problems with the insulin used have hampered development of these systems, the FDA said in a news release.

"We really are trying to get these devices to the market as quickly as possible," Charles Zimliki, leader of the FDA's Artificial Pancreas Working Groups and Critical Path Initiative, said during a news conference Thursday.

That's why the agency has taken the unusual step of developing a guidance for approval, something which is usually done after a device had been developed and tested, he said.

Zimliki said he has no idea when an approved device might be available. To date, the FDA has approved more than 20 clinical studies for artificial pancreas systems.

The FDA's new guidelines make designing, testing and safety and effectiveness requirements more flexible. For example, they propose more flexibility in the choice of clinical trial outcomes, number of patients needed and the length of the trial.

"We really wanted to make a push; we felt like it was a good idea to give academicians and people that aren't familiar with the regulatory process a pathway to develop these systems," Zimliki said. "We want people to move these things forward; we think this guidance will allow people to get a safe and effective product on the market quickly."

In type 1 diabetes, the pancreas produces little or no insulin, an essential hormone necessary for controlling blood sugar. People with type 1 diabetes have to monitor their blood sugar throughout the day, and calculate how much insulin they need to lower their blood sugar, which is delivered using a syringe or insulin pump.

An artificial pancreas system combines an insulin pump and a continuous glucose monitor with a sensor placed under the patient's skin. The pump and monitor work together, tracking blood sugar and automatically pumping measured doses of insulin as determined by a computer algorithm.

These systems help eliminate, or reduce the severity of dangerous drops in blood sugar by stopping insulin administration when blood sugar levels near a predetermined threshold.

The device is not a cure, but it might reduce dangerous high and low blood sugar levels, giving patients a better quality of life and reducing the risk of diabetes-related complications, the FDA said.

The new guidelines recommend a three-phase clinical study progression "so that studies may move to an outpatient setting as quickly as possible." The agency is also suggesting other ways to streamline the testing process, including ways to use existing safety and effectiveness data for the components that make up the system, and allowing data from clinical studies done outside of the United States to be used in the approval process.

In addition, those conducting the clinical trials have the option of demonstrating that the system controls blood sugar as well as standard therapies, or showing that it gives better blood sugar control when compared to other therapies.

"When final, the guidance will help manufacturers and investigators assemble submissions for clinical trials as well as product-approval submissions," the FDA said.

In June, the FDA released a draft guidance on safety and effectiveness goals for researchers and industry in developing the Low Glucose Suspend System, a first-generation artificial pancreas system. Those results helped inform this new guidance, Zimliki said

Hurdles in developing these systems include making sure the implanted sensors remain clear, the need to periodically recalibrate blood sugar monitors, problems with the software needed to operate insulin infusion pumps, problems creating algorithms to deliver insulin that take into account how long it takes the body to absorb it, the need for a faster-acting insulin and the overall development of safer and more reliable algorithms.

Another issue is the lack of a glucagon formulation that can be used in infusion pumps. Glucagon is a hormone used to treat severe low blood sugar. "There is a need for a glucagon formulation that is stable over several days and can be delivered by an infusion pump," the FDA said.

More information

For more on type 1 diabetes, visit the Nemours Foundation.

SOURCE: Dec. 1, 2011, teleconference with: Charles L. Zimliki, Ph.D., leader, Artificial Pancreas Working Groups and Critical Path Initiative, U.S. Food and Drug Administration

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Medicare Cost-Saving Moves Can Backfire
2. Idaho House Moves State Closer to Health Care Disaster
3. California Moves Toward Listing BPA as Reproductive Toxin
4. Sun Spark Purity Moves Aggressively into the Market of Pure Lidocaine Powder and Caffeine Powder
5. Bella Medspa Moves into New Newtown Bucks County Office
6. LazyTown Sportacus and Michelle Obama moves Washington DC
7. Mind Reading Moves Closer to Reality
8. Recent Studies Show MAstertuck℠ Technique Removes Large Amounts of Body Fat without Tummy Tuck Surgery
9. Artificial Pancreas for Type 1 Diabetes Moves Closer to Reality
10. Recent Book Moves Beyond Defensive Medicine, Tackles Entitlement Reform
11. Astra HR Moves its Corporate Headquarters to King Farm, Rockville, MD
Post Your Comments:
Related Image:
FDA Moves to Speed Development of Artificial Pancreas Systems 
(Date:10/9/2015)... ... , ... With the FCPX LUT Vibrance pack from Pixel Film Studios, editors ... Lookup Table that contains a mathematical formula for modifying an image. The LUT changes ... with 60 vibrant CUBE LUT files. , Inspired by many YouTube make-up ...
(Date:10/9/2015)... ... 09, 2015 , ... Dentist in Huntington Beach , ... that uses clear, plastic aligners. This alternative to braces has become wildly popular ... patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so patients ...
(Date:10/9/2015)... Stockton, CA (PRWEB) , ... October 09, 2015 ... ... year anniversary of their “Agents of Change” program, a community improvement initiative that ... The newest charity to benefit from the assistance of Confidence Plus Insurance is ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental health hospital ... mental illness, the stigma associated with mental illness causes many to hide away in ... importance of supporting teens with mental illness , providing teens with comprehensive diagnostic ...
(Date:10/9/2015)... ... , ... Most people assume that Chinese food is more nutritious than American ... T’ai Chi Master and integrative medicine guru Steven Aung, MD agrees with that assessment, ... that they potentially complement one another, with each supplying nutritional elements the other may ...
Breaking Medicine News(10 mins):
... Sales and Marketing Veteran to Drive International Retail Expansion, ... Group and New WrinkleFree Brand Line ExtensionIRVINE, Calif., Jan. ... developer and distributor of medically developed and efficacy-based skin ... mass market retail locations throughout the U.S., announced today ...
... The following statement can be attributed to Michael ... has consistently said two things: We are not ... But we have urged public policy makers to ... merger without conditions, because without conditions the merger ...
... (Nasdaq: OMCL ), a leading provider of system solutions to acute healthcare ... quarter 2008 financial results. , What: Omnicell ... webcast, When: January ... Lipps, chairman, president and chief executive officer, ...
... Maine, Jan. 21 IDEXX Laboratories, Inc. (Nasdaq: ... quarter and full-year financial results for Friday, January 30, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... can lead to failure, , , WEDNESDAY, Jan. 21 (HealthDay ... a common cause of kidney transplant failure may help ... polyomavirus nephropathy, which affects about 9 percent of kidney ... adults but can cause serious problems for people with ...
... CAMBRIDGE, Mass. -- Schizophrenia may blur the boundary between ... that is involved in self-reflection, and thus causing an ... brain imaging study has found. , The traditional ... and emotions that characterize the disease are caused by ...
Cached Medicine News:
(Date:10/9/2015)... , October 9, 2015 ClinicalKey ... 7-9   Elsevier , ... and services, today launched ClinicalKey for Nursing , a ... tailored to meet the unique needs of nursing professionals. Attendees ... Atlanta , Oct. 7-9, will have the opportunity ...
(Date:10/9/2015)... 9, 2015 Eli Lilly and Company (NYSE: ... and approximately 50 new jobs to its research and development ... New York, New York . ... space will include a translational immuno-oncology hub and a Lilly ... collaborative access to cutting-edge drug discovery capabilities, including chemistry and ...
(Date:10/9/2015)... 2015 Der " JCA-Mauvernay Award ... Kondo und Dr.   Junko Takita    --> ... geht an Dr.   Yutaka Kondo und Dr. ... " JCA-Mauvernay Award   2015 " geht ... Takita    ™ , das weltweit tätige Schweizer Biopharmazieunternehmen, ...
Breaking Medicine Technology:
... DIEGO, May 2, 2012  Trovagene, Inc. (Pink Sheets: ... initiated development of a diagnostic test to determine the ... from urine specimens. The proprietary test (U.S. patent application ... determination of carrier status in males. The ...
... 2, 2012 Official journal of the American ... world-leading provider of scientific, technical and medical information products and ... the American Association for Geriatric Psychiatry (AAGP) to ... ( AJGP ) beginning in January 2013. ...
Cached Medicine Technology:
... 4 Dot with 955R Red/Green glasses ... presence of binocular vision. Consists of ... discs: two green, one red and ... any distance. Patient wears red/green glasses ...
20 foot distance 22-1/2" X 11-1/2". This test for illiterate patients has HOTV letters on one side and Allen figures on the other....
Angled 30 degree shaft. 13 mm from tip to bend with 2.5 mm hook curved tip. Polished finished. Overall length excluding hub: 35 mm, 1.4 inches....
McIntyre-Binkhorst, length 18 mm....
Medicine Products: